CN109432085A - Application of the eurycomanone in preparation prevention and treatment male's Delayed onset hypogonadism drug, food and health care product - Google Patents
Application of the eurycomanone in preparation prevention and treatment male's Delayed onset hypogonadism drug, food and health care product Download PDFInfo
- Publication number
- CN109432085A CN109432085A CN201811466308.XA CN201811466308A CN109432085A CN 109432085 A CN109432085 A CN 109432085A CN 201811466308 A CN201811466308 A CN 201811466308A CN 109432085 A CN109432085 A CN 109432085A
- Authority
- CN
- China
- Prior art keywords
- eurycomanone
- delayed onset
- drug
- application
- male
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UCUWZJWAQQRCOR-OKNZMGBLSA-N eurycomanone Chemical compound O1C(=O)[C@H](O)[C@@]2(O)C(=C)[C@@H](O)[C@@]3(O)[C@@H]4[C@@]5(C)[C@H](O)C(=O)C=C(C)[C@@H]5C[C@@H]1[C@]42CO3 UCUWZJWAQQRCOR-OKNZMGBLSA-N 0.000 title claims abstract description 50
- UCUWZJWAQQRCOR-UHFFFAOYSA-N Pasakbumin A Natural products O1C(=O)C(O)C2(O)C(=C)C(O)C3(O)C4C5(C)C(O)C(=O)C=C(C)C5CC1C42CO3 UCUWZJWAQQRCOR-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 239000009947 eurycomanone Substances 0.000 title claims abstract description 48
- 230000003111 delayed effect Effects 0.000 title claims abstract description 28
- 206010058359 Hypogonadism Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 229940079593 drug Drugs 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000002265 prevention Effects 0.000 title claims abstract description 10
- 235000013305 food Nutrition 0.000 title claims abstract description 9
- 230000036541 health Effects 0.000 title claims abstract description 9
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- -1 patch Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- 230000007423 decrease Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- 230000006870 function Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 4
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 description 4
- 210000002149 gonad Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000007466 Male Infertility Diseases 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- RINHYCZCUGCZAJ-UHAHJPEESA-N (2s,3r,4s,5s,6r)-2-[(e)-3-phenylprop-2-enoxy]-6-[[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC\C=C\C=2C=CC=CC=2)O1 RINHYCZCUGCZAJ-UHAHJPEESA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- JJYVNURTNGHITH-UHFFFAOYSA-N rosavin Natural products OC1COC(OCC2OC(OC(=O)C=Cc3ccccc3)C(O)C(O)C2O)C(O)C1O JJYVNURTNGHITH-UHFFFAOYSA-N 0.000 description 1
- IEBFEMIXXHIISM-UHFFFAOYSA-N rozarin Natural products OC1C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC=CC=2C=CC=CC=2)O1 IEBFEMIXXHIISM-UHFFFAOYSA-N 0.000 description 1
- RINHYCZCUGCZAJ-UHFFFAOYSA-N rozavin Natural products OC1C(O)C(O)COC1OCC1C(O)C(O)C(O)C(OCC=CC=2C=CC=CC=2)O1 RINHYCZCUGCZAJ-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides application of the eurycomanone in preparation prevention and treatment male's Delayed onset hypogonadism drug, food and health care product, are related to technical field of new application of medicine.By the embodiment of the present invention, it can be concluded that, the present invention provides eurycomanones in the new application for preventing and treating male's Delayed onset hypogonadism.
Description
Technical field
The present invention relates to technical field of new application of medicine, and in particular to eurycomanone prevents and treats male's Delayed onset sexual gland function in preparation
The application that can decline in disease drug, food and health care product.
Background technique
Male's Delayed onset hypogonadism: middle-aging male with age, generates generally after 45 years old
Male's Delayed onset hypogonadism.Its main clinic symptoms is sexual hypoesthesia, erectile dysfunction, sperm quantity and quality
Decline, so as to cause male infertility.Also there is hectic fever, battle array sweat, agitation, palpitaition, uncomfortable in chest, fluctuation of blood pressure, sleep disturbance, agitation not
Peace, frightened, absent minded, failure of memory, thinking reactive depression, the judgement of cognitive ability, especially space and mathematics push away
The decline of reason ability；Anxiety, sorrow, depression, life interest decline, self-confidence decline.Physical strength and endurance decline are easy fatigue, are complete
Body is out of strength, is easy to fall；Muscular atrophy, muscular strength decline；Abdomen and interior fat increase, central obesity, overweight, cause
Insulin and leptin resistance, many symptoms for type II diabetes and metabolic syndrome occur.Bone density decline, osteoporosis, bone
Amount reduces, increases the risk of fracture.Erythrocyte number and hemoglobin level decline, cause anaemia；The small of the back, four limbs and joint
Pain.
Eurycomanone is a kind of active constituent of Tongkat Ali, is a kind of diterpene-kind compound, chemical formula C20H24O9, molecule
Measure 408.403, CAS accession number 84633-29-4.Eurycomanone has preventing malaria, removing dampness through diuresis and removing jaundice, sterilization and antiulcer in the prior art
Efficiency, also having improves hypertension and the effect of diabetes, but the prior art does not record eurycomanone also and has which kind of effect.
Summary of the invention
The object of the present invention is to provide eurycomanones in preparation prevention and treatment male's Delayed onset hypogonadism drug, food
Application in product and health care product provides the new purposes of one kind of eurycomanone.
The present invention provides application of the eurycomanone in preparation prevention and treatment male's Delayed onset hypogonadism drug.
Preferably, the eurycomanone is to extract to obtain from Tongkat Ali.
Preferably, the drug includes eurycomanone and medically acceptable auxiliary material.
Preferably, the dosage form of the drug includes injection, capsule, tablet, paste, granule, dispersing agent, solution
Agent, emulsion, suspension, patch, gelling agent or suppository.
The present invention also provides eurycomanones to prepare answering in assisting in preventing and treating male's Delayed onset hypogonadism food
With.
The present invention also provides eurycomanones in preparing assisting in preventing and treating male's Delayed onset hypogonadism health care product
Using.
In the present invention, the eurycomanone by act on Hypothalamus-pituitary-testis gonad axis and inhibit aromatizing enzyme,
Phosphodiesterase plays the effect of prevention and treatment male's Delayed onset hypogonadism.
Specific embodiment
The present invention provides application of the eurycomanone in preparation prevention and treatment male's Delayed onset hypogonadism drug.
In the present invention, the eurycomanone by act on Hypothalamus-pituitary-testis gonad axis and inhibit aromatizing enzyme,
Phosphodiesterase plays the effect of prevention and treatment male's Delayed onset hypogonadism.
In the present invention, the taking dose of the eurycomanone is preferred are as follows: 10 μ g/kg~20mg/kg for each person every day.
In the present invention, the drug preferably includes eurycomanone and medically acceptable auxiliary material.The present invention is to the width
The source of tassel ketone is not particularly limited, and using commercial product, or is extracted and is obtained from Tongkat Ali using conventional method,
Or it is obtained using other methods.
In the present invention, the dosage form of the drug preferably includes injection, capsule, tablet, paste, granule, dispersion
Agent, solution, emulsion, suspension, patch, gelling agent or suppository.The present invention is to the method that eurycomanone is prepared into above-mentioned dosage form
It is not particularly limited with the auxiliary material used, using routine.
The present invention also provides eurycomanones to prepare answering in assisting in preventing and treating male's Delayed onset hypogonadism food
With.
The present invention also provides eurycomanones in preparing assisting in preventing and treating male's Delayed onset hypogonadism health care product
Using.
Eurycomanone of the present invention is subtracted in preparation prevention and treatment male's Delayed onset gonad function combined with specific embodiments below
The application moved back in disease drug, food and health care product is further described in detail, and technical solution of the present invention includes but is not limited to
Following embodiment.
Embodiment 1
Clinical test: therapeutic effect of the eurycomanone to male's Delayed onset hypogonadism
Subject: totally 30 people, male 16 people, 14 people of female, 57~72 years old.
Test method: eurycomanone takes orally 20mg for each person every day, is taken in two divided doses, continuous 5 weeks.Before starting test and test
Point takes hematometry free serum testosterone hormones horizontal and observes various clinical symptoms at the same time respectively after 5 weeks, test knot
Fruit is shown in Table 1.
Function and effect of 1 eurycomanone of table to male's Delayed onset hypogonadism
After continuously taking eurycomanone 5 weeks by people it can be seen from the result of table 1, serum testosterone hormonal readiness obviously rises, male
Property testosterone hormones level improves about 70%, and women improves 140%.Since testosterone levels improve, improving property function accordingly
The clinical symptoms of males' Delayed onset hypogonadism such as energy, physical strength, sleep and spirit.
Embodiment 2
Animal experiment: influence of the eurycomanone to Rat Hormone level
Eurycomanone, purity 98%, rat oral gavage administration, dosage 2.0mg/Kg continuous 8 weeks, observe eurycomanone to phase
The influence of hormone is closed, the physiological saline with drug same volume is given in blank control stomach-filling, and test result is shown in Table 2.
Influence result of 2 eurycomanone of table to hormonal readiness
As can be drawn from Table 2, eurycomanone can obviously increase the testosterone hormones level of rat, while increasing rush corpus luteum secretion and swashing
Plain LH and follicle-stimulating hormone (FSH) FSH are horizontal.In physiological conditions, LH and FSH coordinates to promote the function of interstitial glands jointly, has
It is horizontal conducive to testosterone hormones are improved.Therefore, male's Delayed onset hypogonadism can be effectively relieved in eurycomanone.
Embodiment 3
Animal experiment: influence of the eurycomanone to rat spermatozoa quality and quantity
1.8mg/kg eurycomanone is given to rat oral gavage, successive administration 7 weeks, observes the shadow to rat spermatozoa quality and quantity
It rings, blank control stomach-filling gives the physiological saline with drug same volume, the results are shown in Table 3.
Influence of 3 eurycomanone of table to rat spermatozoa quality and quantity
| Serial number | Index | Saline control | Eurycomanone |
| 1 | Sperm concentration (x106/ mL/g testis) | 15.32±0.98 | 37.25±4.62 |
| 2 | It mates index (%) (Matingindex, %) | 60.00 | 75.00 |
| 3 | Fertility index (%) (Fecundityindex, %) | 75.00 | 100.00 |
| 4 | Fertility index (%) (Fertilityindex, %) | 40.00 | 75.0 |
As can be drawn from Table 3, eurycomanone has a significant effect to the quality and quantity of rat spermatozoa, can make the number of rat spermatozoa
Amount improves 1 times or more, and significantly improves mating index, fertility index and fertility index, therefore eurycomanone can be used for treating
Male sexual disfunction and male sterility due to caused by testosterone hormones deficiency, and then treat male's Delayed onset gonad function
Decline disease.
Embodiment 4
Animal experiment: influence of the eurycomanone to enhancing physical strength and endurance
36 mouse are divided into 4 groups at random, respectively Tongkat Ali prepared product group, eurycomanone group, positive drug control group and
Blank control group.Positive drug control is the gadol extract (rhodioside in the extract that is prepared using customary preparation methods
Mass percentage >=1%, Rosavin mass percentage >=3%), dosage 0.6g/kg；Using customary preparation methods
Prepare Tongkat Ali prepared product, the eurycomanone that Tongkat Ali prepared product is 20% containing mass percentage, dosage 15mg/kg；
Eurycomanone purity 98.6%, dosage 3.0mg/kg；Blank control is physiological saline；Gastric infusion, after continuous 28d to mouse into
The measurement of row swimming time, the results are shown in Table 4.
The antifatigue effect of 4 eurycomanone of table
| Group | Swimming time/min |
| Blank control group | 58.82±9.88 |
| Positive controls | 100.98±17.25 |
| Tongkat Ali prepared product group | 120.73±28.32 |
| Eurycomanone | 118.23±22.15 |
As can be drawn from Table 4, the swimming power that eurycomanone can be obviously prolonged mouse exhausts the time, and it is relatively strong to illustrate that eurycomanone has
Antifatigue effect.Since fatigue is also one of the important clinical symptom of male's Delayed onset hypogonadism, wide tassel
Ketone has stronger treatment male Delayed onset hypogonadism effect.
By above embodiments, it can be concluded that, eurycomanone can effectively treat male's Delayed onset hypogonadism, this
Invention provides a kind of new purposes of eurycomanone.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (6)
1. application of the eurycomanone in preparation prevention and treatment male's Delayed onset hypogonadism drug.
2. application according to claim 1, which is characterized in that the eurycomanone is to extract to obtain from Tongkat Ali.
3. application according to claim 1, which is characterized in that the drug includes eurycomanone and medically acceptable auxiliary
Material.
4. application according to claim 1 or 3, which is characterized in that the dosage form of the drug include injection, capsule,
Tablet, paste, granule, dispersing agent, solution, emulsion, suspension, patch, gelling agent or suppository.
5. eurycomanone is preparing the application in assisting in preventing and treating male's Delayed onset hypogonadism food.
6. eurycomanone is preparing the application in assisting in preventing and treating male's Delayed onset hypogonadism health care product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811466308.XA CN109432085A (en) | 2018-12-03 | 2018-12-03 | Application of the eurycomanone in preparation prevention and treatment male's Delayed onset hypogonadism drug, food and health care product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811466308.XA CN109432085A (en) | 2018-12-03 | 2018-12-03 | Application of the eurycomanone in preparation prevention and treatment male's Delayed onset hypogonadism drug, food and health care product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109432085A true CN109432085A (en) | 2019-03-08 |
Family
ID=65555462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811466308.XA Pending CN109432085A (en) | 2018-12-03 | 2018-12-03 | Application of the eurycomanone in preparation prevention and treatment male's Delayed onset hypogonadism drug, food and health care product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109432085A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112121049A (en) * | 2020-08-28 | 2020-12-25 | 嘉兴市第一医院 | Application of cis-atracurium in preparation of medicine for treating male hypogonadism |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103408564A (en) * | 2013-08-16 | 2013-11-27 | 李玉山 | Process for extracting and purifying eurycomanone from Eurycoma longifolia plants |
| CN106366092A (en) * | 2016-08-29 | 2017-02-01 | 湖南华诚生物资源股份有限公司 | Industrial preparation method for separating high-purity eurycomanone from eurycoma longifolia |
| CN106474167A (en) * | 2015-08-25 | 2017-03-08 | 沈阳药科大学 | Eurycoma longifolia extract product, eurycomanone and its preparation method and application |
| CN108864128A (en) * | 2017-05-11 | 2018-11-23 | 北京罗瑞生物科技有限公司 | Four kinds of guassin industrial production process and its prepare drug, health food new application |
-
2018
- 2018-12-03 CN CN201811466308.XA patent/CN109432085A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103408564A (en) * | 2013-08-16 | 2013-11-27 | 李玉山 | Process for extracting and purifying eurycomanone from Eurycoma longifolia plants |
| CN106474167A (en) * | 2015-08-25 | 2017-03-08 | 沈阳药科大学 | Eurycoma longifolia extract product, eurycomanone and its preparation method and application |
| CN106366092A (en) * | 2016-08-29 | 2017-02-01 | 湖南华诚生物资源股份有限公司 | Industrial preparation method for separating high-purity eurycomanone from eurycoma longifolia |
| CN108864128A (en) * | 2017-05-11 | 2018-11-23 | 北京罗瑞生物科技有限公司 | Four kinds of guassin industrial production process and its prepare drug, health food new application |
Non-Patent Citations (1)
| Title |
|---|
| TAMBI M等: "Standardised water-soluble extract of Eurycoma longifolia, Tongkat ali, as testosterone booster for managing men with late-onset hypogonadism", 《ANDROLOGIA》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112121049A (en) * | 2020-08-28 | 2020-12-25 | 嘉兴市第一医院 | Application of cis-atracurium in preparation of medicine for treating male hypogonadism |
| CN112121049B (en) * | 2020-08-28 | 2022-02-01 | 嘉兴市第一医院 | Application of cis-atracurium in preparation of medicine for treating male hypogonadism |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PERLA et al. | Suprarenal cortical hormone and salt in the treatment of pneumonia and other severe infections | |
| Castillo et al. | Syndrome of rudimentary ovaries with estrogenic insufficiency and increase in gonadotropins | |
| CN103417953B (en) | Application of recombined ganoderma lucidum immnoregulation protein (rLZ-8) in preparation of medicine for treating melanin tumor | |
| Maud et al. | Ethno-pharmacological screening of Vernonia amygdalina and Cleome gynandra traditionally used in Childbirth in Western Uganda | |
| CN103341135B (en) | Gel agent for treating arthralgia and preparing method thereof | |
| Lindbjerg | Juvenile rheumatoid arthritis: a follow-up of 75 cases | |
| JP6270869B2 (en) | New uses for Catalpol | |
| CN109432085A (en) | Application of the eurycomanone in preparation prevention and treatment male's Delayed onset hypogonadism drug, food and health care product | |
| CN107050115A (en) | The new application of Chinese patent drug neck waist health | |
| Bang et al. | Low-salt Diet in Treatment of Hypertension | |
| Milhorat et al. | Studies in Diseases of Muscle: III. Metabolism of Creatine and Creatinine in Myasthenia Gravis, Including a Study of the Excretion of Nucleosides and Nucleotides | |
| CN109260235A (en) | A kind of application of composition in preparation prevention and treatment constipation drug or health care product | |
| Bookman et al. | THE METABOLISM IN A CASE OF MYASTHENIA GRAVIS, WITH CONSIDERATIONS ON THE ADMINISTRATION OF CALCIUM AND OF GLANDULAR PREPARATIONS. | |
| Daminov | Disorders of Sexual Development in Men | |
| BROUGHER | PITUITARY CACHEXIA REPORT OF A PATIENT TREATED WITH ANTERIOR PITUITARY EXTRACT | |
| Ormond | Bradycardia due to Spontaneous Hypoglycemia: Report of a Case | |
| Nusriya et al. | Management Of Frozen Shoulder In Diabetes Mellitus Through Valuka Sveda (Ushma Method)–A Case Series | |
| Hurxthal | Treatment of gigantism: Observations on a pituitary giant for six years | |
| RU2456994C2 (en) | Treatment-and-preventive agent for relieving constipation | |
| Bussell | Symptomatic treatment of myotonia atrophica | |
| CN115769881A (en) | Bee product double-layer tablet for improving nonspecific lumbago and preparation method thereof | |
| CN103251921A (en) | Pharmaceutical composition for treating deficiency of both yin and yang, and preparation method, preparation and application thereof | |
| CN107468894A (en) | A kind of capsule medicine for treating hyperthyroidism and preparation method thereof | |
| CN106109529A (en) | Chinese medicine emetic compositions, its preparation method and application thereof | |
| CN109331022A (en) | Improving female ovary function improves the composition and preparation process of female skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190308 |
|
| RJ01 | Rejection of invention patent application after publication |